The current body of evidence on the efficacy and safety of aflibercept for agerelated macular degeneration (AMD) is steadily growing as large clinical trials and observational studies are continually completed. Our aim was to analyse 1-year visual acuity (VA) outcomes in response to aflibercept therapy and identify factors affecting treatment response using evidence generated from a pooled analysis of current studies. A literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) revealed 12 studies meeting inclusion and exclusion criteria for statistical analysis. Treatment posology, baseline patient characteristics, study type, sample size and 12-month change in VA were pooled in a meta-analysis with VA change as the main outcome. Data were then stratified by study design and posology in subgroup analyses. A meta-regression was conducted to regress 12-month VA change against posology, baseline VA and age. Users of aflibercept experienced an overall increase of 7.37 letters (95% confidence interval: 6.27-8.48, p heterogeneity: <0.001) in VA at 12 months of follow-up. In subgroup analyses, mean VA change was higher for randomized control trials and cohorts following regular posology (>7 injections/year) compared to observational studies and irregular posology. The meta-regression showed larger VA gains with regular posology compared to an irregular posology, and decreased effect size as age increased. This meta-analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. Increased injection frequency and younger age demonstrates a trend with improved outcomes.
Introduction
Already the leading cause of blindness in older adults of developed countries, age-related macular degeneration (AMD) is projected to affect 196 million adults in 2020, rising to 288 million in 2040 (Wong et al. 2014 ). The disease is further divided into wet (neovascular) AMD (wAMD) and dry or non-neovascular AMD, the former of which is more severe and carries a grimmer prognosis. Although an array of potential therapeutic targets exists, the main pharmacological treatment of wAMD is anti vascular endothelial growth factor (anti-VEGF) therapy. Two anti-VEGF drugs (ranibizumab and aflibercept) are commonly used for the treatment of wAMD, while bevacizumab, another anti-VEGF developed for several types of cancers, is commonly used in an off-label fashion in many countries (Santarelli et al. 2015) . Aflibercept (Eylea Ò , the newest anti-VEGF drug, has been shown to have comparable efficacy to the more widely used ranibizumab (Thomas et al. 2013; Heier et al. 2016) especially when comparing bimonthly injections of aflibercept (after a three-monthly loading dose) compared to monthly ranibizumab (Heier et al. 2012 ), and appears to be effective for patients resistant to ranibizumab therapy (Ruiz Ramos et al. 2015) . The current body of evidence on the efficacy and safety of aflibercept is broad and steadily growing as large clinical trials and observational studies are continually completed.
The main measurement of efficacy in wAMD therapy is the maintenance or improvement in VA. The multi-faceted nature of measurable visual outcomes has resulted in differences in the reporting of published results. For example, the unit of measurement for best corrected VA may be reported in standardized Early Treatment of Diabetic Retinopathy Study (EDTRS) letters read, the minimum angle of resolution (logMAR units), or in Snellen fractions (Elliott 2016) . Changes in anatomical outcomes such as macular or foveal thickness, measured by optical coherence tomography (OCT), and neovascular lesion size or area have also been used to indicate effectiveness of AMD treatments. Differences in posologies applied to aflibercept use is often inconsistent between practitioners, and remains a focal point of anti-VEGF research. The timing of subsequent doses varies from monthly injections to a pro re nata (as needed) basis with typically poorer results for pro re nata (PRN) posology (Szabo et al. 2015) .
Prior meta-analyses have focused on only a select type of study such as randomized control trials (Ba et al. 2015) , or subsets of drug users, i.e. patients who are refractory to ranibizumab (Seguin-Greenstein et al. 2016 ). Hence, a more inclusive systematic review of up-to-date knowledge is needed to study the efficacy of aflibercept. Similarly, a thorough analysis of patient variables is needed, as heterogeneity may affect the results reported in these trials.
We undertook a meta-analysis to quantify the efficacy of 2.0 mg aflibercept using both randomized controlled trials (RCTs) and observational studies to maximize statistical power. In addition, we aimed to identify patient and study factors that may affect the reporting of outcomes through a meta-regression model. Our primary outcome was VA change from baseline to 12 months using a pooled analysis of selected studies, which was stratified based on factors such as study design, posology and drug naivety. Secondary outcomes included correlation coefficients describing the direction and magnitude of the relationship between study parameters (posology, drug naivety, age and baseline VA) and 12-month VA change.
Materials and Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were used in designing and reporting the systematic review. A systematic search was conducted to find studies reporting VA change at 12 months after initiation of 2.0 mg aflibercept therapy in patients with wAMD compared to alternative therapies for wAMD.
Search strategy & eligibility
An aggregate of multiple electronic databases including Pubmed (Medline), EMBASE and individual journal portals was searched through the University of British Columbia library database . The MedMeme master database was also used to search for published content that may have been missed in the earlier searches. In addition, the contents and reference lists of prior meta-analyses and systematic reviews were hand-searched. Searches contained published content up to March 2017, when the last search was initiated. Combinations of the terms: 'aflibercept', 'prospective', 'VA', 'visual outcomes', 'macular degeneration', and 'AMD' were used. Results were filtered using the in-laid restrictions: 'Full Text Online' and 'Scholarly & Peer-Review'. Eligibility assessment was performed independently in a standardized manner by one reviewer and the list of included studies were reviewed by a second reviewer. Disagreements between reviewers was resolved by consensus. No restrictions were imposed for publication date, patient age, treatment history, baseline VA or baseline anatomical measurements.
Inclusion criteria
Studies included in the analysis were randomized control trials (RCT's) and observational studies such as retrospective chart reviews and observational case-series that reported the efficacy of aflibercept on VA. Inclusion criteria included: (i) Peer-reviewed publications in English, (ii) indication for wAMD, (iii) patient populations who received no prior anti-VEGF treatment and (iv) VA outcomes reported as Early Treatment Diabetic Retinopathy Study (EDTRS) letter units or units that were convertible into EDTRS (i.e. logMAR).
Exclusion criteria
Exclusion criteria included: (i) therapy given at doses other than 2.0 mg, (ii) incomplete articles (i.e. incomplete or missing methods sections) and (iii) no inclusion of VA outcomes at both baseline and 12 months following treatment initiation or no VA change from baseline to 12 months.
Data extraction
We developed a data extraction sheet to summarize study characteristics and main end-points.
Information extracted from each individual study included: (i) Type of study (RCT or observational/single arm prospective), (ii) dosage frequency, (iii) sample size, (iv) baseline age and (v) change in VA from baseline at 12 months.
To explore variability between study results, we hypothesized a priori that effect size may differ depending on the methodology applied. Studies were to be grouped and analysed based on study design and posology.
Statistical analysis
First, a meta-analysis of all studies meeting statistical inclusion criteria (reported standard deviations and mean VA change from baseline) were pooled to assess the mean change in VA from baseline to 12 months. VA change was ascertained from VA reported at baseline and at 12 months. If a study did not report both a mean and standard deviation for VA at baseline and at 12 months, we excluded the group from statistical analysis. However, if a mean VA change with standard deviation was reported from baseline to 12 months, it was included. Subgroup analyses were conducted in which the studies were separated by study design (prospective RCT versus observational) and posology (regular versus irregular). Regular posology was defined as either monthly or monthly for the first 3 months (39 mo) followed by bimonthly injections. Irregular posology was defined as PRN (PRN -as needed) or 39 monthly followed by PRN. If posology was unclear in the written report, a mean number of injections ≥7 in the first 12 months following treatment initiation was deemed as regular. Prior to analysis, logMAR units of VA were converted to EDTRS letters for studies providing logMAR as a measure of VA. One study provided statistical measures in Snellen units (SeguinGreenstein et al. 2016) , which was first converted to logMAR units, then followed the same conversion protocol into EDTRS letters. We constructed a meta-regression to further explore heterogeneity. The meta regression was weighed by the inverse of its variance. The change in letters from baseline at 12 months was regressed against the following variables: dose, baseline VA and age. All analyses were conducted using the R software version 3.3.2 (Free Software Foundation, Boston, MA, USA).
Methodological & risk of bias assessment
The Downs and Black checklist was used to evaluate the methodological quality of both randomized and nonrandomized studies (Downs & Black 1998) . Scores from 26 items in the checklist reflect the reporting, external validity and internal validity (bias and confounding) of each study. A higher score indicates a higher methodological quality. Validity of the checklist is reported elsewhere (Downs & Black 1998) . Articles were reviewed independently by two authors (MG and ME) and disagreements were resolved by consensus. Heterogeneity p-values were calculated as an indicator of the risk of bias across the studies. Figure 1 shows how the studies were selected for inclusion in our analysis. Our search resulted in 76 study titles that were screened for eligibility criteria, 25 were excluded based on inclusion criteria, 17 based on exclusion criteria, and 22 studies based on missing statistical parameters such as mean and standard deviation for VA at baseline and at 12 months. The final analysis contained 16 heterogenous patient populations described by 12 studies (Heier et al. 2012; Oishi et al. 2015; Gillies et al. 2016; Kim et al. 2016; Oubraham-Mebroukine et al. 2016; Park et al. 2016; Talks et al. 2016; Eleftheriadou et al. 2017; Ohnaka et al. 2017; Rasmussen et al. 2017; Takayama et al. 2017) ; 2 RCTs and 10 observational (Fig. 2, Tables 1 and S1 ). Table 1 summarizes the characteristics of the 12 studies were included for statistical analysis. Several studies reported the outcomes of multiple heterogenous study groups (i.e. separated based on posology) (Talks et al. 2016; Ohnaka et al. 2017; Takayama et al. 2017) . Hence, the study characteristics and statistical analyses were based on individual study populations as opposed to entire studies. 4 Studies investigated both aflibercept and ranibizumab for VA outcomes (Heier et al. 2012; Kim et al. 2016; Park et al. 2016) , including the landmark VIEW 1 and VIEW 2 trials. Twelve of the 16 study groups (75%) followed observational protocol, including single-arm interventional designs and retrospective chart reviews (Table 1) . For posology, a greater proportion of aflibercept studies (63%) used a regular posology. The size of the studies ranged from 36 to 990 and a total of 3367 patients were included for analysis. Mean baseline VA ranged from 48.5 to 67 EDTRS letters. All included patients received no prior treatment with anti-VEGF therapy.
Results

Study selection
Study characteristics
Change in VA at 12 months Users of aflibercept experienced an overall increase in VA at 12 months of 7.37 letters [95% confidence interval (CI): 6.27-8.48]. Of the 16 study populations, 12 reported statistically significant improvements from baseline. The pooled VA for RCT studies was 8.82 letters (95% CI: 7.34-10.30) and for observational studies was 5.97 letters (95% CI: 5.09-6.85; Table 2 ). The pooled VA for regular users was 7.49 letters (95% CI: 6.17-8.81), whereas for irregular users it was 6.67 letters (95% CI: 4.73-8.60).
Methodological & risk of bias assessment
A summary of the methodological assessment using the Downs and Black checklist is provided in Table 3 . Scores for methodological quality ranged from 14 to 20 (mean = 17; median = 16). The largest source of variation between studies was the reporting category, with differences in reporting of adverse events, confounders, estimates of random variability and characteristics of patients lost to follow-up. Strong evidence of heterogeneity was observed in the overall pooling of all included studies (p < 0.001), and in the subgroup analysis for regular users (p < 0.001) and RCT studies (p = 0.012). Lower heterogeneity was observed in the subgroup analysis for irregular users (p = 0.875) and observational studies (p = 0.931).
Meta-regression
The meta-regression also showed a statistically non-significant trend in * When studies stratified study subjects based on study design or treatment protocol, the groups were treated as separate populations in statistical analysis.
posology; higher increase in VA gain at 12 months was observed with regular posology compared to irregular posology (Table 4) . A statistically non-significant decrease in effect size was observed as age increased (Table 4) .
Discussion
This review was undertaken to summarize the current literature on VA effects of aflibercept for wAMD patients and to examine clinical factors that may affect patient variability in clinical outcomes. The results of this meta-analyses demonstrated significant increases in VA outcomes at 1 year in users of 2.0 mg aflibercept. A higher increase in VA was observed for regular versus irregular posology, and for RCTs versus non-RCT studies. Results from the meta-regression analysis also revealed an increasing trend in VA change with more regular posology, as well as a decreasing trend with older age. In comparison to prior landmark clinical trials on the efficacy of aflibercept in wAMD (Heier et al. 2012) , the mean change in VA reported in this meta-analysis was lower. Landmark trials such as the VIEW 1 and VIEW 2 trials administered aflibercept following regular posologies, which differed from the combination of regular and irregular posologies of the studies included in our meta-analysis. Upon further stratification, the pooled results for RCT patients and patients following regular posologies reflected the results of the VIEW 1 and VIEW 2 trials more closely. The overall pooled increase of 7.37 letters was higher than reported in a meta-analysis of observational studies by Zhang et al. (2017) , the most recent meta-analysis conducted prior to this publication and similar to a meta-analysis of landmark clinical trials conducted by Szabo et al. in (2015) . The study by Szabo et al. (2015) also compared aflibercept users to ranibizumab users, which yielded statistically similar effectiveness for both drugs. Aflibercept-induced improvements in VA are not limited to wAMD; similar results have been concluded in patients with diabetic macular oedema, the significance of which cannot be directly compared with the results of this study (Korobelnik et al. 2015) .
A similar trend of larger changes in VA with increased frequency of aflibercept dosing was observed in a Bayesian network meta-analysis by Szabo et al. (2015) . The study reported the greatest improvements in VA for monthly 0.5 mg aflibercept, followed by 39 monthly then bimonthly doses, with PRN doses exhibiting no significant improvements. A majority of the studies in our meta-analysis with irregular posologies followed a PRN approach, whereas others followed treat-and-extend or wait-and-see approach, defined as treatment only when patients presented with symptomatic disease or when a clinician deemed treatment to be necessary. In these circumstances, asymptomatic but destructive pathology in the retina may cause progressive damage, resulting in more difficult management of the wAMD.
There was a considerable amount of variation between retrospective studies, resulting in a larger variance in the pooled effect size for both retrospective study populations (p heterogenity: 0.932) and irregular posology (p heterogenity: 0.875) in comparison to RCT's (p heterogenity: 0.012) and regular posology (p heterogenity: <0.001). This highlights the effects of strict eligibility criteria in RCT's to minimize variability from patient factors like comorbidities and baseline VA. In a controlled clinical setting, the efficacy of aflibercept is likely higher than our calculated pooled mean. In a realworld setting, however, patients inevitably present with a high degree of A negative trend between age and VA change was observed, which may reflect poorer visual outcomes at a later age of presentation. However, this was not statistically significant, which may be due to a smaller pooled study population and a weak correlation at an estimate of À0.3 letters gained per year in age (Table 4) . In prior studies, a negative trend was observed between baseline VA and long-term visual effects of ranibizumab therapy (Dugel et al. 2016; Razi et al. 2016) . Dugel et al. (2016) describe the trend as a 'plateau effect' in which the VA gained by anti-VEGF use reaches a maximum over the time-course of treatment. However, this trend was not observed in our regression analysis, which indicated a statistically non-significant positive trend. This inconsistency may be a result of the relatively smaller body of evidence available for aflibercept.
Changes in VA are a focal point of clinical care; VA improvements provided by anti-VEGF therapy have been correlated with functional improvements impacting daily living such as reading speed, reading acuity and contrast sensitivity at 1 year (Munk et al. 2013) . Hence, studying VA improvements provides a representative indicator of the clinical benefit of aflibercept.
Limitations
The evidence on na€ ıve aflibercept users remains modest, with a majority of current literature based on two landmark trials published in 2012 (Heier et al. 2012) . Although results from the observational studies were similar to RCT analyses, reporting standards and study protocol rigour may differ. Hence, observational studies, which are traditionally more prone to heterogeneity, have lower data quality compared to RCT's. Many aflibercept studies examined patients who were switched from previous ranibizumab therapy, limiting the data pool for na€ ıve users of the drug. Consequently, the two aforementioned landmark trials dominate the RCT portion of the aflibercept meta-analyses, and account for 42% of the weighted total of the main meta-analysis (Fig. 2) , which skews the results towards that of the trials. Further, no subgroup analysis was conducted for subtypes of AMD such as polypoidal choroidal vasculopathy and retinal angiomatous proliferation.
Conclusions
The results of our meta-analysis strongly suggest improved VA outcomes at 12 months in patients with wAMD for aflibercept, comparable to but slightly lower than landmark trials. Increased injection frequency and younger age demonstrates a trend with improved outcomes. However, variability in patient factors at baseline, in treatment regimens and in the physiological response warrants further research into these topics.
